Insider Trading Alert - INO, NAV And TRLA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 15, 2014, 62 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $15.81 to $34,205,434.59.

Highlighted Stocks Traded by Insiders:

Inovio Pharmaceuticals (INO) - FREE Research Report

Kim Jong Joseph who is Chief Executive Officer at Inovio Pharmaceuticals bought 25,000 shares at $2.25 on April 15, 2014. Following this transaction, the Chief Executive Officer owned 6.0 million shares meaning that the stake was reduced by 0.42% with the 25,000-share transaction.

The shares most recently traded at $2.45, up $0.20, or 8.16% since the insider transaction. Historical insider transactions for Inovio Pharmaceuticals go as follows:

  • 4-Week # shares bought: 190,000
  • 12-Week # shares bought: 190,000
  • 24-Week # shares bought: 190,000

The average volume for Inovio Pharmaceuticals has been 8.1 million shares per day over the past 30 days. Inovio Pharmaceuticals has a market cap of $641.2 million and is part of the health care sector and drugs industry. Shares are down 7.93% year-to-date as of the close of trading on Tuesday.

Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Currently there are 4 analysts that rate Inovio Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INO - FREE

TheStreet Quant Ratings rates Inovio Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Inovio Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Navistar International (NAV) - FREE Research Report

Icahn Carl C who is 10% Owner at Navistar International bought 1.0 million shares at $33.28 on April 15, 2014. Following this transaction, the 10% Owner owned 14.3 million shares meaning that the stake was reduced by 7.72% with the 1.0 million-share transaction.

The shares most recently traded at $34.62, up $1.34, or 3.87% since the insider transaction.

The average volume for Navistar International has been 1.4 million shares per day over the past 30 days. Navistar International has a market cap of $2.7 billion and is part of the consumer goods sector and automotive industry. Shares are down 11.68% year-to-date as of the close of trading on Tuesday.

Navistar International Corporation, through its subsidiaries, manufactures and sells commercial and military trucks, diesel engines, and school and commercial buses; and provides service parts for trucks and diesel engines worldwide. Currently there are 4 analysts that rate Navistar International a buy, 2 analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NAV - FREE

TheStreet Quant Ratings rates Navistar International as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Navistar International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Trulia (TRLA) - FREE Research Report

Inkinen Sami who is Director at Trulia sold 5,800 shares at $31.05 on April 15, 2014. Following this transaction, the Director owned 763,203 shares meaning that the stake was reduced by 0.75% with the 5,800-share transaction.

Flint Peter who is Chief Executive Officer at Trulia sold 8,000 shares at $31.06 on April 15, 2014. Following this transaction, the Chief Executive Officer owned 1.5 million shares meaning that the stake was reduced by 0.55% with the 8,000-share transaction.

The shares most recently traded at $30.47, down $0.59, or 1.93% since the insider transaction. Historical insider transactions for Trulia go as follows:

  • 4-Week # shares sold: 65,898
  • 12-Week # shares sold: 235,683
  • 24-Week # shares sold: 461,808

The average volume for Trulia has been 1.9 million shares per day over the past 30 days. Trulia has a market cap of $1.1 billion and is part of the technology sector and internet industry. Shares are down 11.94% year-to-date as of the close of trading on Tuesday.

Trulia, Inc. provides tools to research homes and neighborhoods for consumers through Web and mobile applications. The company, through its tools, also enables real estate professionals to market their listings. Currently there are 4 analysts that rate Trulia a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on TRLA - FREE

TheStreet Quant Ratings rates Trulia as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Trulia Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Investors Need to Closely Watch Mario Draghi's Speech at Jackson Hole: Market Recon

Investors Need to Closely Watch Mario Draghi's Speech at Jackson Hole: Market Recon

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round